Research News and Research

RSS

New program educates parents on fun, healthy mealtime ideas

How did the simple act of eating become so difficult? Between basic nutrition, the obesity epidemic, allergies, food recalls, and chemical contaminants, feeding children a healthy diet has never been so complicated. Eat Healthy, a new program from Healthy Child Healthy World, makes it easy.

15 Sep 2009

GlaxoSmithKline's Votrient will take significant market share away from Pfizer's Sutent by 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, following its launch and uptake, GlaxoSmithKline's angiogenesis inhibitor Votrient (formerly Armala) will garner sales of $640 million by 2018 and will take significant market share away from Pfizer's Sutent. In 2008, Sutent had accounted for 61 percent of sales in the angiogenesis inhibitor drug class.

15 Sep 2009

IMPROVE HF clinical trial results presented at annual HFSA meeting

Twenty-four month findings from IMPROVE HF, (The Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting), funded by Medtronic, Inc., demonstrated that clinics using the process improvement program increased adherence to evidence-based, guideline-recommended care by 82 and 62 percent, respectively, for cardiac resynchronization therapy (CRT) and implantable cardioverter-defibrillator (ICD) use, and 80 percent for aldosterone antagonist use, all relative to baseline results.

15 Sep 2009

KYTHERA initiates proof-of-concept trial of its ATX-104 light-activated facial contouring agent

KYTHERA Biopharmaceuticals, Inc. (KYTHERA) today announced that it has initiated a first-in-human, proof-of-concept study evaluating the safety, tolerability, persistence and histological effects of ATX-104, a light-activated facial contouring agent.

15 Sep 2009

Cytheris' INSPIRE study data of HIV-infected patients with low CD4 T cell counts announced

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced presentation of data from an interim analysis of CLI-107-06 (INSPIRE), a Phase I/IIa study of HIV-infected patients with low CD4 T cell counts. The patients were treated with a three-injection cycle of the Company’s investigative immune-modulator, recombinant human Interleukin-7 (CYT107).

15 Sep 2009

A.P. Pharma and Merial sign license and development agreement for a long-acting pain management product

A.P. Pharma (Nasdaq:APPA), a specialty pharmaceutical company, today announced that it has entered into a license and development agreement with Merial, a world leading animal health company, for a long-acting pain management product.

15 Sep 2009

OptiVol for accurate prediction of heart failure

Fluid monitoring with OptiVol® Fluid Status Monitoring is a more accurate predictor of worsening heart failure compared to daily weight monitoring in heart failure patients with implantable devices, according to results released today from the FAST (Fluid Accumulation Status Trial) clinical trial.

15 Sep 2009

New data reveals the evolution of Immunoglobulin E

Immunoglobulin E (IgE) is the main actor in the drama of allergy. The biological role of IgE in the immune response of an organism and the lack of control leading to allergy is the research topic of Gernot Achatz, Molekular Biology, University of Salzburg. At the 2nd European Congress of Immunology ECI 2009 held in Berlin the scientist presents new data revealing the evolution of IgE.

15 Sep 2009

Significant uptake of medical imaging equipment in Ghana

Ghana's healthcare industry is experiencing growth across a range of sectors. However, the drive towards improved diagnostic capability has led to high demand for medical imaging devices.

15 Sep 2009

Genova gains access to Big Pharma's distribution channels

GENova Biotherapeutics Inc. ("GENova"), a cancer drug acquisition and development company, is pleased to announce it has gained access to distribution channels for its promising drug targets through a recently-signed deal with Bridge BioResearch Plc. ("Bridge BioResearch").

15 Sep 2009

Less than five percent of employers plan to reduce health and productivity programs: IBI

Today the non-profit Integrated Benefits Institute (IBI) released a preliminary result from a survey of more than 400 employers indicating that less than five percent plan to reduce or eliminate health and productivity programs. This flies in the face of recent reports that employers are likely to eliminate wellness programs as a cost-saving measure.

15 Sep 2009

Researchers study the degree of verbal impairment in AD patients

A postgraduate researcher at the University of Hertfordshire has found that Alzheimer's Disease (AD) results in greater language impairments in more highly-educated than less learned patients.

15 Sep 2009

XBox chip is a cheaper alternative to other forms of parallel processing hardware: Study

A new study by a University of Warwick researcher has demonstrated that researchers trying to model a range of processes could use the power and capabilities of a particular XBox chip as a much cheaper alternative to other forms of parallel processing hardware.

15 Sep 2009

Clinical trial data of Genous Bio-engineered R stent to be presented

Data from multiple clinical trials of the world's first pro-healing stent, OrbusNeich's Genous Bio-engineered R stent, and preclinical data from Combo Bio-engineered Sirolimus Eluting Stent will be presented next week at the Transcatheter Cardiovascular Therapeutics symposium, TCT 2009, in San Francisco.

15 Sep 2009

Celebrity supports Alzheimer's Association

National Football League (NFL) wide receiver for the Buffalo Bills, Terrell Owens, will support the Alzheimer's Association this fall by having his own team for Memory Walk(R).

15 Sep 2009

New book on human genetics helps to unravel complex human diseases

Many human diseases-including Alzheimer's disease, schizophrenia, cancer, and cardiovascular disease-are caused by multiple genetic variants and the interaction of those variants with the environment. Because such diseases lack a clear-cut inheritance pattern, sophisticated technological approaches and statistical analyses are required to determine their underlying cause.

15 Sep 2009

Targeted Molecular Diagnostics to offer digital pathology services in Beijing

Targeted Molecular Diagnostics (TMD), a Quintiles Central Laboratory, announced today the availability of digital pathology services in Beijing, China. The services add to Quintiles offerings used in the development of therapies to treat the world’s most pressing health issues, including cancer.

15 Sep 2009

Gentic circuits that cause mucous hyper-production identified

Scientists have identified the main genetic switch that causes excessive mucous in the lungs, a discovery that one day could ease suffering for people with chronic lung diseases like asthma and cystic fibrosis, or just those fighting the common cold.

15 Sep 2009

NSF International certification for COLD-FX(R)

Afexa Life Sciences Inc. ("Afexa") (TSX:FXA) today announced that COLD-FX(R) has received the highest sports certification in North America from the leading product safety and banned substances testing body for elite athletes.

15 Sep 2009

35 percent of Iraq veterans seek post traumatic stress disorder treatment

The Veterans' Administration should expect a high volume of Iraq veterans seeking treatment of post traumatic stress disorder, with researchers anticipating that the rate among armed forces will be as high as 35%, according to the Management Insights feature in the current issue of Management Science, the flagship journal of the Institute for Operations Research and the Management Sciences (INFORMS-).

15 Sep 2009